SCHEMBL378967

SCHEMBL378967

C[C@H](NC(=O)C1(c2ccc(F)cc2)CCN(C(=O)OC(C)(C)C)CC1)c1ccc(F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.60
ALOX15 P16050 1/20 0.60
ATM Q13315 1/20 0.60
HSD17B10 Q99714 1/20 0.46
PTGER4 P35408 1/20 0.44
TACR1 P25103 1/20 0.43
HDAC2 Q92769 2/20 0.43
RORC P51449 2/20 0.43
HDAC1 Q13547 1/20 0.43
HTT P42858 2/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
RAB9A P51151 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
NPY1R P25929 1/20 0.41
SLC6A4 P31645 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31382020 0.81 TSHR (0.51) TSHRALOX15ATMHDAC2RORC
SCHEMBL396197 0.81 TSHR (0.53) TSHRALOX15ATMTACR1HDAC2
SCHEMBL13092254 0.80 KIT (0.44) TACR1HTTNPC1ALDH1A1MAPT
SCHEMBL378735 0.79 NPY1R (0.52) TSHRALOX15ATMTACR1NPC1
SCHEMBL4036608 0.79 ATM (0.51) TSHRALOX15ATMPTGER4TACR1
SCHEMBL6543732 0.79 TSHR (0.80) TSHRALOX15ATMHSD17B10TACR1
SCHEMBL378416 0.79 TSHR (0.50) TSHRALOX15ATMHDAC2RORC
SCHEMBL7908737 0.79 PANK3 (0.48) TSHRALOX15TACR1HTTALDH1A1
SCHEMBL5673260 0.78 ATM (0.47) TSHRALOX15ATMHDAC2RORC
SCHEMBL2470899 0.76 OPRL1 (0.61) TSHRALOX15ATMHSD17B10TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324250-B2 Piperidine derivatives as NK3 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2012-12-04 US disclosed
EP-2408745-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2012-01-25 EP disclosed
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2010-10-07 US disclosed
WO-2010106081-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256126-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HTR3A, OPRL1, OPRK1 TSHR 895/4885ALOX15 3133/4885ATM 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.